A groundbreaking study led by the University of Edinburgh has identified significant blood differences in people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to healthy individuals. Published in EMBO Molecular Medicine, using data from the UK Biobank and replicated in the US, the research highlights consistent biomarkers linked to chronic inflammation and insulin resistance, offering hope for future diagnostic tools.
The study, the largest of its kind, analyzed over 3,000 blood biomarkers in 1,455 ME/CFS patients and 131,000 healthy controls. Advanced statistical models accounted for variables like age, sex, and activity levels, revealing 116 biomarker differences common across both sexes. Notably, the strongest disparities were found in patients experiencing post-exertional malaise, a hallmark symptom where minor exertion worsens symptoms.
Researchers emphasized that these biomarkers are likely a result of ME/CFS, not reduced activity levels, countering outdated claims that the condition is psychological or due to deconditioning. The findings underscore ME/CFS as a biological illness with measurable blood traits.
Professor Chris Ponting, a lead author, stated: “We see people’s ME/CFS in their blood. This evidence should dispel any lingering perception that it’s caused by exercise intolerance.” Dr. Sjoerd Beentjes added: “Our methods provide strong proof that ME/CFS directly affects blood traits, independent of activity.”
The study marks a critical step toward developing a blood test for ME/CFS, which currently lacks diagnostic tools or treatments. By validating these biomarkers, the research opens doors for further investigations into the disease’s mechanisms and potential therapies.
Add comment